NewAmsterdam Pharma Company N.V. WarrantNAMSW
About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Employees: 77
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.22% less ownership
Funds ownership: 1.43% [Q4 2024] → 1.21% (-0.22%) [Q1 2025]
9% less funds holding
Funds holding: 11 [Q4 2024] → 10 (-1) [Q1 2025]
34% less capital invested
Capital invested by funds: $18.8M [Q4 2024] → $12.3M (-$6.43M) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for NAMSW.
Financial journalist opinion
We haven’t received any recent news articles for NAMSW.